Bile acid signaling, metabolism, and aging

Abstract

Bile acids (BAs) serve not only as key facilitators of lipid absorption but also as crucial signaling molecules regulating glucose and lipid metabolism, inflammation, and overall energy homeostasis. Aging profoundly alters BA metabolism, characterized by shifts in biosynthetic pathways, compositional changes, disrupted receptor-mediated signaling, and alterations in gut microbiota interactions. These age-related changes contribute to the onset and progression of metabolic conditions, including type 2 diabetes, obesity, metabolic dysfunction-associated fatty liver disease, and neurodegenerative disorders. An increased abundance of hydrophobic and cytotoxic BAs has been associated with systemic inflammation, metabolic rigidity (disruption of metabolic flexibility), and organ dysfunction. Targeting BA signaling-through pharmacological modulation of farnesoid X receptor and Takeda G protein-coupled receptor 5 or microbiota-directed therapies-offers promising strategies to mitigate aging-related metabolic decline. A deeper understanding of how BA metabolism evolves over the lifespan may unveil novel interventions to promote healthy aging and prevent age-related disease.

Keywords

Aging / Bile acids (BAs) / Gut microbiota / Metabolic disorders / Neurodegeneration

Authors’ contributions

Ji Sun: Writing - original draft, Resources, Conceptualization. Shili Zhang: Writing - review & editing, Writing - original draft, Resources. Lihua Jin: Writing - review & editing, Writing - original draft, Resources, Conceptualization. Wendong Huang: Writing - review & editing, Supervision, Funding acquisition, Conceptualization.

Declaration of competing interest

The authors declare no conflicts of interest.

Acknowledgements

In preparing this manuscript, authors were supported by R01DK124627 and R01DK138665, as well as John Hench Founda-tion, Irina & George Schaeffer Foundation and ARDMRI Innovative Pilot Project Award. The figures were created using BioRender (BioRender.com).

References

[1] Watson KB, Wiltz JL, Nhim K, Kaufmann RB, Thomas CW, Greenlund KJ Tr.Trends in multiple chronic conditions among US adults, by life stage, behavioral risk factor surveillance system,2013-2023. Prev Chronic Dis. 2025;22:E15. https://doi.org/10.5888/pcd22.240539.

[2] Hashemi R, Rabizadeh S, Yadegar A, et al. High prevalence of comorbidities in older adult patients with type 2 diabetes: a cross-sectional survey. BMC Geriatrics. 2024; 24:873. https://doi.org/10.1186/s12877-024-05483-3.

[3] Li Q, Jiang Y, Song A, Li Y, Xu X, Xu R. The association between chronological age and dyslipidemia: a cross-sectional study in Chinese aged population. Clin Interv Aging. 2023; 18:667-675. https://doi.org/10.2147/CIA.S406237.

[4] Zhao Y, Crimmins EM, Hu P, et al. Prevalence, diagnosis, and management of diabetes mellitus among older Chinese: results from the China health and retirement longitudinal study. Int J Public Health. 2016; 61:347-356. https://doi.org/10.1007/s00038-015-0780-x.

[5] Fuchs CD, Simbrunner B, Baumgartner M, Campbell C, Reiberger T, Trauner M. Bile acid metabolism and signalling in liver disease. J Hepatol. 2025; 82:134-153. https://doi.org/10.1016/j.jhep.2024.09.032.

[6] Fleishman JS, Kumar S. Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets. Signal Transduct Target Ther. 2024; 9:97. https://doi.org/10.1038/s41392-024-01811-6.

[7] Jin L, Shi L, Huang W. The role of bile acids in human aging. Med Rev (2021). 2024; 4:154-157. https://doi.org/10.1515/mr-2024-0003.

[8] Chiang JY. Bile acid metabolism and signaling. Compr Physiol. 2013; 3: 1191-1212. https://doi.org/10.1002/cphy.c120023.

[9] Liu Y, Tu J, Shi L, et al. CYP8B1 downregulation mediates the metabolic effects of vertical sleeve gastrectomy in mice. Hepatology. 2024; 79:1005-1018. https://doi.org/10.1097/hep.0000000000000627.

[10] Fiorucci S, Marchianò S, Distrutti E, Biagioli M. Bile acids and their receptors in hepatic immunity. Liver Res. 2025; 9:1-16. https://doi.org/10.1016/j.livres.2025.01.005.

[11] Wei S, Ma X, Zhao Y. Mechanism of hydrophobic bile acid-induced hepato-cyte injury and drug discovery. Front Pharmacol. 2020; 11:1084. https://doi.org/10.3389/fphar.2020.01084.

[12] Li T, Chiang JY. Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev. 2014; 66:948-983. https://doi.org/10.1124/pr.113.008201.

[13] Wahlström A, Sayin SI, Marschall HU, Bäckhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 2016; 24:41-50. https://doi.org/10.1016/j.cmet.2016.05.005.

[14] Bertolini A, Fiorotto R, Strazzabosco M. Bile acids and their receptors: modulators and therapeutic targets in liver inflammation. Semin Immuno-pathol. 2022; 44:547-564. https://doi.org/10.1007/s00281-022-00935-7.

[15] Ma J, Hong Y, Zheng N, et al. Gut microbiota remodeling reverses aging- associated inflammation and dysregulation of systemic bile acid homeosta-sis in mice sex-specifically. Gut Microbes. 2020; 11:1450-1474. https://doi.org/10.1080/19490976.2020.1763770.

[16] Di Ciaula A, Garruti G, Lunardi Baccetto R, et al. Bile acid physiology. Ann Hepatol. 2017;16:s4-s14. https://doi.org/10.5604/01.3001.0010.5493.

[17] Hofmann AF, Hagey LR. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci. 2008; 65:2461-2483. https://doi.org/10.1007/s00018-008-7568-6.

[18] Di Ciaula A, Bonfrate L, Khalil M, Portincasa P. The interaction of bile acids and gut inflammation influences the pathogenesis of inflammatory bowel disease. Intern Emerg Med. 2023; 18:2181-2197. https://doi.org/10.1007/s11739-023-03343-3.

[19] Frommherz L, Bub A, Hummel E, et al. Age-related changes of plasma bile acid concentrations in healthy adults-results from the cross-sectional Kar-MeN study. PLoS One. 2016; 11:e0153959. https://doi.org/10.1371/journal.pone.0153959.

[20] Bertolotti M, Gabbi C, Anzivino C, et al. Age-related changes in bile acid synthesis and hepatic nuclear receptor expression. Eur J Clin Invest. 2007; 37: 501-508. https://doi.org/10.1111/j.1365-2362.2007.01808.x.

[21] Uchida K, Chikai T, Takase H, et al. Age-related changes of bile acid meta-bolism in rats. Arch Gerontol Geriatr. 1990; 10:37-48. https://doi.org/10.1016/0167-4943(90)90042-5.

[22] Sato K, Kakiyama G, Suzuki M, et al. Changes in conjugated urinary bile acids across age groups. Steroids. 2020; 164:108730. https://doi.org/10.1016/j.steroids.2020.108730.

[23] Bilson J, Scorletti E, Swann JR, Byrne CD. Bile acids as emerging players at the intersection of steatotic liver disease and cardiovascular diseases. Bio-molecules. 2024; 14:841. https://doi.org/10.3390/biom14070841.

[24] van der Werf SD, Huijbregts AW, Lamers HL, van Berge Henegouwen GP, van Tongeren JH. Age dependent differences in human bile acid metabolism and 7 alpha-dehydroxylation. Eur J Clin Invest. 1981; 11:425-431. https://doi.org/10.1111/j.1365-2362.1981.tb02009.x.

[25] Ni Y, Lu M, Xu Y, et al. The role of gut microbiota-bile acids axis in the progression of non-alcoholic fatty liver disease. Front Microbiol. 2022; 13: 908011. https://doi.org/10.3389/fmicb.2022.908011.

[26] Ren Z, Zhao L, Zhao M, et al. Increased intestinal bile acid absorption con-tributes to age-related cognitive impairment. Cell Rep Med. 2024; 5:101543. https://doi.org/10.1016/j.xcrm.2024.101543.

[27] Cai J, Sun L, Gonzalez FJ. Gut microbiota-derived bile acids in intestinal im-munity, inflammation, and tumorigenesis. Cell Host Microbe. 2022; 30: 289-300. https://doi.org/10.1016/j.chom.2022.02.004.

[28] Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human in-testinal bacteria. J Lipid Res. 2006; 47:241-259. https://doi.org/10.1194/jlr.R500013-JLR200.

[29] Bourgin M, Kriaa A, Mkaouar H, et al. Bile salt hydrolases: at the crossroads of microbiota and human health. Microorganisms. 2021; 9:1122. https://doi.org/10.3390/microorganisms9061122.

[30] Jones BV, Begley M, Hill C, Gahan CG, Marchesi JR. Functional and compar-ative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. Proc Natl Acad Sci U S A. 2008; 105:13580-13585. https://doi.org/10.1073/pnas.0804437105.

[31] Buffie CG, Bucci V, Stein RR, et al. Precision microbiome reconstitution re-stores bile acid mediated resistance to Clostridium difficile. Nature. 2015; 517:205-208. https://doi.org/10.1038/nature13828.

[32] Quinn RA, Melnik AV, Vrbanac A, et al. Global chemical effects of the microbiome include new bile-acid conjugations. Nature. 2020; 579:123-129. https://doi.org/10.1038/s41586-020-2047-9.

[33] Ay Ü, Leníček M, Classen A, Olde Damink SWM, Bolm C, Schaap FG. New kids on the block: bile salt conjugates of microbial origin. Metabolites. 2022; 12: 176. https://doi.org/10.3390/metabo12020176.

[34] Garcia CJ, Kosek V, Beltrán D, Tomás-Barberán FA, Hajslova J. Production of new microbially conjugated bile acids by human gut microbiota. Bio-molecules. 2022; 12:687. https://doi.org/10.3390/biom12050687.

[35] Tu J, Wang Y, Jin L, Huang W. Bile acids, gut microbiota and metabolic sur-gery. Front Endocrinol (Lausanne). 2022; 13:929530. https://doi.org/10.3389/fendo.2022.929530.

[36] Salazar J, Durán P, Díaz MP, et al. Exploring the relationship between the gut microbiota and ageing: a possible age modulator. Int J Environ Res Public Health. 2023; 20:5845. https://doi.org/10.3390/ijerph20105845.

[37] Ragonnaud E, Biragyn A. “healthy” Gut microbiota as the key controllers of aging of elderly people. Immun Ageing. 2021; 18:2. https://doi.org/10.1186/s12979-020-00213-w.

[38] Odamaki T, Kato K, Sugahara H, et al. Age-related changes in gut microbiota composition from newborn to Centenarian: a cross-sectional study. BMC Microbiol. 2016; 16:90. https://doi.org/10.1186/s12866-016-0708-5.

[39] Perino A, Demagny H, Velazquez-Villegas L, Schoonjans K. Molecular phys-iology of bile acid signaling in health, disease, and aging. Physiol Rev. 2021; 101:683-731. https://doi.org/10.1152/physrev.00049.2019.

[40] Shi L, Jin L, Huang W. Bile acids, intestinal barrier dysfunction, and related diseases. Cells. 2023; 12:1888. https://doi.org/10.3390/cells12141888.

[41] Sato Y, Atarashi K, Plichta DR, et al. Novel bile acid biosynthetic pathways are enriched in the microbiome of centenarians. Nature. 2021; 599:458-464. https://doi.org/10.1038/s41586-021-03832-5.

[42] Larabi AB, Masson HLP, Bäumler AJ. Bile acids as modulators of gut micro-biota composition and function. Gut Microbes. 2023; 15:2172671. https://doi.org/10.1080/19490976.2023.2172671.

[43] Tian Y, Gui W, Koo I, et al. The microbiome modulating activity of bile acids. Gut Microbes. 2020; 11:979-996. https://doi.org/10.1080/19490976.2020.1732268.

[44] Nie Q, Luo X, Wang K, et al. Gut symbionts alleviate MASH through a sec-ondary bile acid biosynthetic pathway. Cell. 2024; 187:2717- 2734(e33). https://doi.org/10.1016/j.cell.2024.03.034.

[45] Peng Y-L, Wang S-H, Zhang Y-L, et al. Effects of bile acids on the growth, composition and metabolism of gut bacteria. NPJ Biofilms Microbiomes. 2024; 10:112. https://doi.org/10.1038/s41522-024-00566-w.

[46] Hang S, Paik D, Yao L, et al. Bile acid metabolites control TH17 and Treg cell differentiation. Nature. 2019; 576:143-148. https://doi.org/10.1038/s41586-019-1785-z.

[47] Ding L, Yang L, Wang Z, Huang W. Bile acid nuclear receptor FXR and digestive system diseases. Acta Pharm Sin B. 2015; 5:135-144. https://doi.org/10.1016/j.apsb.2015.01.004.

[48] Wang YD, Chen WD, Huang W. FXR, a target for different diseases. Histol Histopathol. 2008; 23:621-627. https://doi.org/10.14670/hh-23.621.

[49] Katafuchi T, Makishima M. Molecular basis of bile acid-FXR-FGF15/19 signaling axis. Int J Mol Sci. 2022; 23:6046. https://doi.org/10.3390/ijms23116046.

[50] Kong B, Wang L, Chiang JY, Zhang Y, Klaassen CD, Guo GL. Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology. 2012; 56:1034-1043. https://doi.org/10.1002/hep.25740.

[51] Kir S, Zhang Y, Gerard RD, Kliewer SA, Mangelsdorf DJ. Nuclear receptors HNF4α and LRH-1 cooperate in regulating Cyp7a1 in vivo. J Biol Chem. 2012; 287:41334-41341. https://doi.org/10.1074/jbc.M112.421834.

[52] Cui JY, Aleksunes LM, Tanaka Y, et al. Bile acids via FXR initiate the expres-sion of major transporters involved in the enterohepatic circulation of bile acids in newborn mice. Am J Physiol Gastrointest Liver Physiol. 2012; 302: G979-G996. https://doi.org/10.1152/ajpgi.00370.2011.

[53] Dekaney CM, von Allmen DC, Garrison AP, et al. Bacterial-dependent up- regulation of intestinal bile acid binding protein and transport is FXR- mediated following ileo-cecal resection. Surgery. 2008; 144:174-181. https://doi.org/10.1016/j.surg.2008.03.035.

[54] Kir S, Beddow SA, Samuel VT, et al. FGF19 as a postprandial, insulin- independent activator of hepatic protein and glycogen synthesis. Science. 2011; 331:1621-1624. https://doi.org/10.1126/science.1198363.

[55] Kliewer SA, Mangelsdorf DJ. Bile acids as hormones: the FXR-FGF15/19 pathway. Dig Dis. 2015; 33:327-331. https://doi.org/10.1159/000371670.

[56] Gadaleta RM, van Erpecum KJ, Oldenburg B, et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in in-flammatory bowel disease. Gut. 2011; 60:463-472. https://doi.org/10.1136/gut.2010.212159.

[57] Wang Y-D, Chen W-D, Moore DD, Huang W. FXR: a metabolic regulator and cell protector. Cell Res. 2008; 18:1087-1095. https://doi.org/10.1038/cr.2008.289.

[58] Qiu Y, Yu J, Ji X, et al. Ileal FXR-FGF15/19 signaling activation improves skeletal muscle loss in aged mice. Mech Ageing Dev. 2022; 202:111630. https://doi.org/10.1016/j.mad.2022.111630.

[59] Zhang L, Yu J, Gao X, et al. Targeting farnesoid X receptor as aging inter-vention therapy. Acta Pharm Sin B. 2025; 15:1359-1382. https://doi.org/10.1016/j.apsb.2025.01.006.

[60] Azizsoltani A, Niknam B, Taghizadeh-Teymorloei M, Ghoodjani E, Dianat- Moghadam H, Alizadeh E. Therapeutic implications of obeticholic acid, a farnesoid X receptor agonist, in the treatment of liver fibrosis. Biomed Pharmacother. 2025; 189:118249. https://doi.org/10.1016/j.biopha.2025.118249.

[61] Papazyan R, Liu X, Liu J, et al. FXR activation by obeticholic acid or nonste-roidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver. J Lipid Res. 2018; 59:982-993. https://doi.org/10.1194/jlr.M081935.

[62] Sun L, Cai J, Gonzalez FJ. The role of farnesoid X receptor in metabolic dis-eases, and gastrointestinal and liver cancer. Nat Rev Gastroenterol Hepatol. 2021; 18:335-347. https://doi.org/10.1038/s41575-020-00404-2.

[63] Lun W, Yan Q, Guo X, et al. Mechanism of action of the bile acid receptor TGR5 in obesity. Acta Pharm Sin B. 2024; 14:468-491. https://doi.org/10.1016/j.apsb.2023.11.011.

[64] Delghandi MP, Johannessen M, Moens U. The cAMP signalling pathway ac-tivates CREB through PKA, p38 and MSK1 in NIH 3T3 cells. Cell Signal. 2005; 17:1343-1351. https://doi.org/10.1016/j.cellsig.2005.02.003.

[65] Maczewsky J, Kaiser J, Gresch A, et al. TGR5 activation promotes stimulus- secretion coupling of pancreatic β-cells via a PKA-dependent pathway. Dia-betes. 2018; 68:324-336. https://doi.org/10.2337/db18-0315.

[66] Doucette CC, Nguyen DC, Barteselli D, et al. Optogenetic activation of UCP1- dependent thermogenesis in brown adipocytes. iScience. 2023; 26:106560. https://doi.org/10.1016/j.isci.2023.106560.

[67] Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009; 10:167-177. https://doi.org/10.1016/j.cmet.2009.08.001.

[68] Shi Y, Su W, Zhang L, et al. TGR5 Regulates macrophage inflammation in nonalcoholic steatohepatitis by modulating NLRP 3 inflammasome activation. Front Immunol. 2020; 11:609060. https://doi.org/10.3389/fimmu.2020.609060.

[69] Wang XX, Luo Y, Wang D, et al. A dual agonist of farnesoid X receptor (FXR) and the G protein-coupled receptor TGR5, INT-767, reverses age-related kidney disease in mice. J Biol Chem. 2017; 292:12018-12024. https://doi.org/10.1074/jbc.C117.794982.

[70] He Y, Liu S, Zhang Y, et al. Takeda G protein-coupled receptor 5 (TGR5): an attractive therapeutic target for aging-related cardiovascular diseases. Front Pharmacol. 2025; 16:1493662. https://doi.org/10.3389/fphar.2025.1493662.

[71] Gou X, Qin L, Wu D, et al. Research progress of Takeda G protein-coupled receptor 5 in metabolic syndrome. Molecules. 2023; 28:5870. https://doi.org/10.3390/molecules28155870.

[72] Pathak P, Liu H, Boehme S, et al. Farnesoid X receptor induces Takeda G- protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism. J Biol Chem. 2017; 292:11055-11069. https://doi.org/10.1074/jbc.M117.784322.

[73] Trabelsi M-S, Daoudi M, Prawitt J, et al. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat Commun. 2015; 6:7629. https://doi.org/10.1038/ncomms8629.

[74] Pathak P, Xie C, Nichols RG, et al. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism. Hepatology. 2018; 68:1574-1588. https://doi.org/10.1002/hep.29857.

[75] Chiang JYL, Ferrell JM.Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy. Am J Physiol Gastrointest Liver Physiol. 2020; 318: G554-G573. https://doi.org/10.1152/ajpgi.00223.2019.

[76] Wang XX, Xie C, Libby AE, et al. The role of FXR and TGR5 in reversing and preventing progression of Western diet-induced hepatic steatosis, inflam-mation, and fibrosis in mice. J Biol Chem. 2022; 298:102530. https://doi.org/10.1016/j.jbc.2022.102530.

[77] Zhu M, Liu X, Liu W, Lu Y, Cheng J, Chen Y. β cell aging and age-related diabetes. Aging. 2021; 13:7691-7706. https://doi.org/10.18632/aging.202593.

[78] Zhang Y, Lee FY, Barrera G, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A. 2006; 103:1006-1011. https://doi.org/10.1073/pnas.0506982103.

[79] Grant SM, DeMorrow S. Bile acid signaling in neurodegenerative and neurological disorders. Int J Mol Sci. 2020; 21:5982. https://doi.org/10.3390/ijms21175982.

[80] Yang G, Jena PK, Hu Y, et al. The essential roles of FXR in diet and age influenced metabolic changes and liver disease development: a multi-omics study. Biomark Res. 2023; 11:20. https://doi.org/10.1186/s40364-023-00458-9.

[81] Xu N, He Y, Zhang C, et al. TGR5 signalling in heart and brain injuries: focus on metabolic and ischaemic mechanisms. Neurobiol Dis. 2024; 192:106428. https://doi.org/10.1016/j.nbd.2024.106428.

[82] Zhang S, Zhou J, Wu W, Zhu Y, Liu X. The role of bile acids in cardiovascular diseases: from mechanisms to clinical implications. Aging Dis. 2023; 14: 261-282. https://doi.org/10.14336/ad.2022.0817.

[83] Chávez-Talavera O, Tailleux A, Lefebvre P, Staels B. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology. 2017; 152:1679- 1694(e3). https://doi.org/10.1053/j.gastro.2017.01.055.

[84] Vettorazzi JF, Ribeiro RA, Borck PC, et al. The bile acid TUDCA increases glucose-induced insulin secretion via the cAMP/PKA pathway in pancreatic beta cells. Metabolism. 2016; 65:54-63. https://doi.org/10.1016/j.metabol.2015.10.021.

[85] Zangerolamo L, Carvalho M, Barssotti L, et al. The bile acid TUDCA reduces age-related hyperinsulinemia in mice. Sci Rep. 2022; 12:22273. https://doi.org/10.1038/s41598-022-26915-3.

[86] Watanabe M, Houten SM, Mataki C, et al. Bile acids induce energy expen-diture by promoting intracellular thyroid hormone activation. Nature. 2006; 439:484-489. https://doi.org/10.1038/nature04330.

[87] Jin LH, Fang ZP, Fan MJ, Huang WD. Bile-ology: from bench to bedside. J Zhejiang Univ Sci B. 2019; 20:414-427. https://doi.org/10.1631/jzus.B1900158.

[88] Clifford BL, Sedgeman LR, Williams KJ, et al. FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption. Cell Metab. 2021; 33:1671- 1684(e4). https://doi.org/10.1016/j.cmet.2021.06.012.

[89] Watanabe M, Houten SM, Wang L, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest. 2004; 113: 1408-1418. https://doi.org/10.1172/jci21025.

[90] Haeusler RA, Astiarraga B, Camastra S, Accili D, Ferrannini E. Human insulin resistance is associated with increased plasma levels of 12α-hydroxylated bile acids. Diabetes. 2013; 62:4184-4191. https://doi.org/10.2337/db13-0639.

[91] Ding L, Zhang E, Yang Q, et al. Vertical sleeve gastrectomy confers metabolic improvements by reducing intestinal bile acids and lipid absorption in mice. Proc Natl Acad Sci U S A. 2021; 118:e2019388118. https://doi.org/10.1073/pnas.2019388118.

[92] Slätis K, Gåfvels M, Kannisto K, et al. Abolished synthesis of cholic acid re-duces atherosclerotic development in apolipoprotein E knockout mice. J Lipid Res. 2010; 51:3289-3298. https://doi.org/10.1194/jlr.M009308.

[93] Oh AR, Bae JS, Lee J, et al. Ursodeoxycholic acid decreases age-related adiposity and inflammation in mice. BMB Rep. 2016; 49:105-110. https://doi.org/10.5483/bmbrep.2016.49.2.173.

[94] Gao T, Feridooni HA, Howlett SE, Pelis RM. Influence of age on intestinal bile acid transport in C57BL/6 mice. Pharmacol Res Perspect. 2017; 5:e00287. https://doi.org/10.1002/prp2.287.

[95] Wu D, Liu J, Guo Z, et al. Natural bioactive compounds reprogram bile acid metabolism in MAFLD: multi-target mechanisms and therapeutic implica-tions. Int Immunopharmacol. 2025; 157:114708. https://doi.org/10.1016/j.intimp.2025.114708.

[96] Bertaggia E, Jensen KK, Castro-Perez J, et al. Cyp8b1 ablation prevents Western diet-induced weight gain and hepatic steatosis because of impaired fat absorption. Am J Physiol Endocrinol Metab. 2017;313:E121-E133. https://doi.org/10.1152/ajpendo.00409.2016.

[97] Gillard J, Clerbaux LA, Nachit M, et al. Bile acids contribute to the develop-ment of non-alcoholic steatohepatitis in mice. JHEP Rep. 2022; 4:100387. https://doi.org/10.1016/j.jhepr.2021.100387.

[98] Nagengast FM, van der Werf SD, Lamers HL, Hectors MP, Buys WC, van Tongeren JM. Influence of age, intestinal transit time, and dietary composi-tion on fecal bile acid profiles in healthy subjects. Dig Dis Sci. 1988; 33: 673-678. https://doi.org/10.1007/bf01540429.

[99] Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 2013; 499:97-101. https://doi.org/10.1038/nature12347.

[100] Bjursell M, Wedin M, Admyre T, et al. Ageing Fxr deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASH. PLoS One. 2013; 8:e64721. https://doi.org/10.1371/journal.pone.0064721.

[101] Kim KH, Choi S, Zhou Y, et al. Hepatic FXR/SHP axis modulates systemic glucose and fatty acid homeostasis in aged mice. Hepatology. 2017; 66: 498-509. https://doi.org/10.1002/hep.29199.

[102] Chen K, Zhao Y, Wang L, Yin Y, Yang L, Luo D. Gut microbiota-regulated bile acids metabolism features in the aging process in mice. Journal of Holistic Integrative Pharmacy. 2022; 3:45-56. https://doi.org/10.1016/S2707-3688(23)00065-1.

[103] Yui S, Kanamoto R, Saeki T. Biphasic regulation of cell death and survival by hydrophobic bile acids in HCT116 cells. Nutr Cancer. 2009; 61:374-380. https://doi.org/10.1080/01635580802582744.

[104] Gadaleta RM, Moschetta A. Metabolic messengers: fibroblast growth factor 15/19. Nat Metab. 2019; 1:588-594. https://doi.org/10.1038/s42255-019-0074-3.

[105] Gonzalez FJ, Jiang C, Patterson AD. An intestinal microbiota-farnesoid x re-ceptor axis modulates metabolic disease. Gastroenterology. 2016; 151: 845-859. https://doi.org/10.1053/j.gastro.2016.08.05.

[106] Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013; 1453:574- 582(e1). https://doi.org/10.1053/j.gastro.2013.05.042.

[107] Castillo V, Figueroa F, González-Pizarro K, Jopia P, Ibacache-Quiroga C. Pro-biotics and prebiotics as a strategy for non-alcoholic fatty liver disease, a narrative review. Foods. 2021; 10:1719. https://doi.org/10.3390/foods10081719.

[108] Carino A, Cipriani S, Marchianò S, et al. BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis. Sci Rep. 2017; 7:42801. https://doi.org/10.1038/srep42801.

[109] Nie K, Li Y, Zhang J, et al. Distinct bile acid signature in Parkinson’s disease with mild cognitive impairment. Front Neurol. 2022; 13:897867. https://doi.org/10.3389/fneur.2022.897867.

[110] Mulak A. Bile acids as key modulators of the brain-gut-microbiota axis in Alzheimer's disease. J Alzheimers Dis. 2021; 84:461-477. https://doi.org/10.3233/jad-210608.

[111] Xing C, Huang X, Wang D, et al. Roles of bile acids signaling in neuro-modulation under physiological and pathological conditions. Cell Biosci. 2023; 13:106. https://doi.org/10.1186/s13578-023-01053-z.

[112] Romero-Ramírez L, Mey J. Emerging roles of bile acids and tgr5 in the central nervous system: molecular functions and therapeutic implications. Int J Mol Sci. 2024; 25:9279. https://doi.org/10.3390/ijms25179279.

[113] Kiriyama Y, Nochi H. The biosynthesis, signaling, and neurological functions of bile acids. Biomolecules. 2019; 9:232. https://doi.org/10.3390/biom9060232.

[114] Nho K, Kueider-Paisley A, MahmoudianDehkordi S, et al. Altered bile acid profile in mild cognitive impairment and Alzheimer’s disease: relationship to neuroimaging and CSF biomarkers. Alzheimer’s Dement. 2019; 15:232-244. https://doi.org/10.1016/j.jalz.2018.08.012.

[115] McMillin M, DeMorrow S. Effects of bile acids on neurological function and disease. FASEB J. 2016; 30:3658-3668. https://doi.org/10.1096/fj.201600275R.

[116] Ehtezazi T, Rahman K, Davies R, Leach AG. The pathological effects of circulating hydrophobic bile acids in Alzheimer’s disease. J Alzheimers Dis Res. 2023; 7:173-211. https://doi.org/10.3233/adr-220071.

[117] MahmoudianDehkordi S, Arnold M, Nho K, et al. Altered bile acid profile associates with cognitive impairment in Alzheimer’s disease-An emerging role for gut microbiome. Alzheimer’s Dement. 2019; 15:76-92. https://doi.org/10.1016/j.jalz.2018.07.217.

[118] Li P, Killinger BA, Ensink E, et al. Gut microbiota dysbiosis is associated with elevated bile acids in Parkinson’s disease. Metabolites. 2021; 11:29. https://doi.org/10.3390/metabo11010029.

[119] Shan H-M, Zang M, Zhang Q, et al. Farnesoid X receptor knockout protects brain against ischemic injury through reducing neuronal apoptosis in mice. J Neuroinflammation. 2020; 17:164. https://doi.org/10.1186/s12974-020-01838-w.

[120] Zhang Z, Zhang Y, Peng H, et al. Decoding TGR5: a comprehensive review of its impact on cerebral diseases. Pharmacol Res. 2025; 213:107671. https://doi.org/10.1016/j.phrs.2025.107671.

[121] Palmela I, Correia L, Silva RF, et al. Hydrophilic bile acids protect human blood-brain barrier endothelial cells from disruption by unconjugated bili-rubin: an in vitro study. Front Neurosci. 2015; 9:80. https://doi.org/10.3389/fnins.2015.00080.

[122] Yanguas-Casás N, Barreda-Manso MA, Nieto-Sampedro M, Romero- Ramírez L. TUDCA: an agonist of the bile acid receptor GPBAR1/TGR5 with anti-inflammatory effects in microglial cells. J Cell Physiol. 2017; 232: 2231-2245. https://doi.org/10.1002/jcp.25742.

[123] Wu X, Lv YG, Du YF, et al. Neuroprotective effects of INT-777 against Aβ(1- 42)-induced cognitive impairment, neuroinflammation, apoptosis, and syn-aptic dysfunction in mice. Brain Behav Immun. 2018; 73:533-545. https://doi.org/10.1016/j.bbi.2018.06.018.

[124] Yildirim Simsir I, Soyaltin UE, Cetinkalp S. Glucagon like peptide-1 (GLP-1) likes Alzheimer’s disease. Diabetes Metabol Syndr. 2018; 12:469-475. https://doi.org/10.1016/j.dsx.2018.03.002.

[125] Chen Q, Ma H, Guo X, Liu J, Gui T, Gai Z. Farnesoid X receptor (FXR) aggra-vates amyloid-β-triggered apoptosis by modulating the cAMP-response element-binding protein (CREB)/brain-derived neurotrophic factor (BDNF) pathway in vitro. Med Sci Monit. 2019; 25:9335-9345. https://doi.org/10.12659/msm.920065.